Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma · line 1 · Acalabrutinib + Venetoclax + Obinutuzumab (AVO), fixed-duration 14 cycles (AMPLIFY)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-AVO-CLL-1L |
| ID | IND-CLL-1L-AVO |
|---|---|
| Type | Indication |
| Status | pending_clinical_signoff |
| Diseases | DIS-CLL |
| Sources | None declared |
Notes
STUB — pending Co-Lead sign-off. Aggressive-track for CLL 1L fixed-duration triple therapy. AMPLIFY (NCT03836261, Brown JR et al., NEJM 2025): 3-arm (AV vs AVO vs chemoimmuno, n=867). Primary endpoint: PFS. AVO vs chemo HR 0.42 (36-mo PFS 83.1% vs 66.5%); AV vs chemo HR 0.65 (36-mo PFS 76.5%). AVO NOT directly compared to VenO (CLL14) — cross-trial only. Obi starts cycle 2 (not cycle 1) with acalabrutinib lead-in; venetoclax ramp cycle 3. AMPLIFY enrolled patients without del(17p)/TP53 mutation. Applicability to del(17p)/TP53-mutated CLL: limited data; BTKi-based regimens generally preferred for high-risk cytogenetics per NCCN — discuss per patient.
Used By
Algorithms
ALGO-CLL-1L- ALGO-CLL-1L